Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Interest & Investment Income (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Interest & Investment Income for 4 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Interest & Investment Income fell 65.7% to $1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.0 million, a 53.53% decrease, with the full-year FY2025 number at $7.0 million, down 53.53% from a year prior.
  • Interest & Investment Income was $1.2 million for Q4 2025 at Phathom Pharmaceuticals, down from $1.4 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $4.3 million in Q1 2024 to a low of $7000.0 in Q1 2022.
  • A 4-year average of $2.0 million and a median of $1.6 million in 2023 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: soared 20757.14% in 2023, then tumbled 65.7% in 2025.
  • Phathom Pharmaceuticals' Interest & Investment Income stood at $1.3 million in 2022, then surged by 160.14% to $3.3 million in 2023, then rose by 4.84% to $3.5 million in 2024, then crashed by 65.7% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Interest & Investment Income are $1.2 million (Q4 2025), $1.4 million (Q3 2025), and $1.8 million (Q2 2025).